FTC lands $16 million judgment against supplement firms
This article was originally published in The Tan Sheet
The U.S. District Court for the Northern District of Georgia has issued a final monetary judgment and permanent prohibitions against the marketers of dietary supplement products Thermalean and Lipodrene for weight loss and Spontane-ES for erectile dysfunction. Defendants National Urological Group, Hi-Tech Pharmaceuticals and several others are found liable for $15.8 million in deceptive sales based on claims that their products caused 19 percent loss in total body weight and were clinically proven to treat 90 percent of men with ED, the Federal Trade Commission says Jan. 15. The marketers also are barred from making such claims in the absence of scientific evidence. The court granted FTC's motion for summary judgment in June, after the defendants unsuccessfully argued that the "non-actionable puffery" in their ads granted them protection under the FTC Act (1"The Tan Sheet" June 16, 2008, p. 8)
You may also be interested in...
A recent court ruling emphasizes Federal Trade Commission strategies to prevent companies from repeatedly making false claims, stretching substantiation data, using deceptive endorsements and creating shell businesses
Research takes deep dive into the implications around exempting certain orphan drugs that may qualify for the Inflation Reduction Act’s Medicare price negotiation program, including the effect of the exemption on Medicare spending and the revenue potential of those drugs.
In the latest venture capital and private equity funding deals in China, SanegeneBio, Argo Biopharma and Ausper Biopharma raised a combined $136m on the back of their early-stage small interfering RNA and antisense oligonucleotide assets.